Abstract:To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA). Angiography revealed a regional lesion with severe stenosis in the distal RCA. No lesions were detected in the rest segment of coronary arteries [Figure 1a]. Intravascular ultrasound (IVUS) confirmed abundant fibrous plaques with plaque rupture in the lesion site [Figure 1b]. After predilatation, a XINSORB scaffold whose size was 3.0 mm × 18.0 mm was implanted. Repeated angiography showed the scaffold was well deployed. Minimal luminal diameter (MLD) was 2.95 mm while in-scaffold residual stenosis was 7.4% [Figure 1c]. No malapposition was detected under IVUS [Figure 1d]. The scaffold area was 6.62 ± 0.57 mm2. The patient was discharged 2 days after the procedure. Neither major adverse cardiac events nor stent thrombus related events were recorded. During the next 6 months, the patient recovered well without recurrent ischemic symptoms. Dual antiplatelet therapy was maintained. Angiography at 6-month follow-up showed the scaffold remained patent without significant neointimal hyperplasia. In-scaffold MLD and percent of diameter stenosis was 2.73 mm and 8.8% respectively, therefore the in-scaffold late luminal loss was calculated as 0.22 mm [Figure 1e]. The area of scaffold, lumen and neointima was 6.69 ± 0.52 mm2, 6.44 ± 0.46 mm2 and 0.24 ± 0.11 mm2 under IVUS [Figure 1f]. No difference was detected between the scaffold area after the procedure and 6-month follow-up (P = 0.82). Optical coherence tomography showed that all struts remained the appearance of preserved box. The struts were embedded in neointima and well-apposed. Figure 1 (a and b) Regional lesion with severe stenosis in the distal RCA; IVUS showed abundant fibrous plaques; (c and d) Final result after treated with a XINSORB scaffold; the struts were well apposed under IVUS; (e and f) The vessel remained patent at 6-month ... Bioresorbable XINSORB scaffold is a balloon-expandable stent system. The scaffold is composed of poly-L-lactic acid (PLLA) as its backbone. Poly-D-L-lactic acid mixed with PLLA is coated on the scaffold surface, containing sirolimus and controlling its elution. The dose of sirolimus is 8 μg/mm. About 80% of anti-proliferative drugs are eluted in 28 days ex vivo. Thickness of strut is 160 μm. The device is stored at 4°C.[1,2] The safety and effectiveness of bioresorbable scaffold (BRS) are confirmed by ABSORB studies.[3,4,5] The XINSORB scaffold is the first domestically made BRS by Chinese company. Promising clinical and angiographic outcomes have been established in this patient. Some advice should be followed when using this device. First, mandatory predilatation must be performed. A balloon to artery ratio of 1:1 is recommended. Second, the scaffold should not be deployed until 90 s after it exposes to the blood. Third, the scaffold should be slowly expanded from 0 to 4 atm during the first 10 s. After that, the scaffold can be fully expanded at a pressure not exceeding 14 atm for 30 s. Lastly, postdilatation was allowed with a 3.0 mm or 3.25 mm noncompliance balloon that was shorter than the implanted scaffold. This is the first implantation of a domestic BRS. Currently, a single-arm clinical trial of XINSORB scaffold is being carried out in Zhongshan Hospital, Fudan University and Chinese People's Liberation Army General Hospital. Large scale and long-term follow-up are required to confirm the substantial benefits of XINSORB scaffold in treating coronary lesions of Chinese population.

Three-year Clinical Outcomes of a Sirolimus-Eluting Bioresorbable Scaffold (XINSORB) and a Metallic Stent to Treat Coronary Artery Stenosis.

Twelve-month Angiographic and Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold and a Metallic Stent in Patients with Coronary Artery Disease

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Final Report of the 5-Year Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in the Treatment of Single De Novo Coronary Lesions in a First-in-human Study

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Comparison of the “late Catch-Up” Phenomenon Between BuMA Supreme and XIENCE Stents Through Serial Optical Coherence Tomography at 1–2 Month and 2 Year Follow-Ups: A Multicenter Study

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

A randomized comparison of healing response of the BuMA Supreme stent and Xience stent at one- and two-month follow-up: PIONEER-II OCT randomized controlled trial.

Six-month Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in Treating Single De Novo Lesions in Human Coronary Artery.

Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds and Metallic Stents: Three-Year Clinical Outcomes from the ABSORB China Randomised Trial

Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China Trial.

Mid-to-long term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in coronary artery diseases: a meta-analysis of 7321 patients

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China

Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis

A Head to Head Comparison of XINSORB Bioresorbable Sirolimus-Eluting Scaffold Versus Metallic Sirolimus-Eluting Stent: 180 Days Follow-Up in a Porcine Model

5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique

First‐in‐man Study of a Thinner‐strut Sirolimus‐eluting Bioresorbable Scaffold (FUTURE‐I): Three‐year Clinical and Imaging Outcomes

A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.

Healing Score of the Xinsorb Scaffold in the Treatment of De Novo Lesions: 6-Month Imaging Outcomes

TCT-567 Long-Term Outcomes with an Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent Versus a Cobalt-Chromium Everolimus-Eluting Stent in Single De Novo Coronary Lesions: Four-Year Results of the TARGET I Randomized Controlled Trial